Akebia finally inflects on observed dosing — but the tape keeps bleeding

Vafseo patients jump 60% with 86% refill adherence, yet the stock is down ~35% in 90 days as the 2027 dialysis-bundle cliff prices in.

AKBA · Earnings Call · 2026-05-07

Vafseo finally inflects on observed dosing

After four quarters of flat demand and a bruising education in patient adherence, Akebia Therapeutics finally printed the launch quarter its CEO promised. Q1 2026 Vafseo net product revenue of $15.8M was the highest quarter for the product since U.S. approval, and the underlying metrics moved decisively. The mechanism is the shift to observed dosing protocols — giving the drug in-center, three times a week, when the patient is already in the chair — which has repaired the adherence leak that sank 2025. As John Butler put it, “we're very pleased and excited by the start to 2026” — John Butler, Chief Executive Officer · 2026-05-07 — and the numbers back the tone. The magnitude of the change is real. Patients on therapy jumped ~60% quarter-over-quarter to roughly 7,500, with Q1 new patient starts the highest since launch. The number of prescribers writing for Vafseo rose ~28% to about 1,025, and — a key diversification marker — roughly 30% of writers now come from organizations other than U.S. Renal Care. Nick Grund was explicit about the engine:

By the end of the quarter, USRC had observed dosing protocols available in nearly all of their clinics as did IRC and DCI... approximately 2/3 of all Vafseo patients were being treated 3 times weekly... First refill adherence rates through the end of March were approximately 86% for patients treated under an observed dosing protocol.
Nicholas Grund, Chief Commercial Officer · 2026-05-07

That 86% first-refill figure is the whole story. In 2025 the same metric ran in the mid-70s, and the launch stalled at roughly $11–12M a quarter because patients started on once-daily home dosing simply weren't refilling — a problem made worse by anemia managers who were quick to switch patients back to ESAs on any hemoglobin dip. Six months ago management was still conceding the hockey stick hadn't arrived. John Butler admitted in February, “demand basically has been flat. We had $12 million in the third quarter, $11 million in the fourth quarter...” — John Butler, CEO · 2026-02-26 and Nick Grund cautioned that “we're not going to see this hockey stick inflection. It is going to be steady growth month-over-month.” — Nicholas Grund, Chief Commercial Officer · 2026-02-26 Q1 2026, with 60% patient growth and 86% adherence, is as close to that inflection as this launch has come. The biggest remaining unlock is DaVita, which management expects to adopt an observed dosing protocol in the second half of 2026. John Butler was blunt about the upside: “that pool is so much bigger that we need to tap into it.” — John Butler, Chief Executive Officer · 2026-05-07 DaVita represents the single largest growth opportunity in a $1B-plus dialysis anemia market where Vafseo is still a fraction of patients.

The pipeline gets its second act

Akebia is no longer just a one-drug story. The April R&D Day pivoted the narrative toward a Kidney Disease pipeline anchored by three candidates: praliciguat (a soluble guanylate cyclase stimulator in Phase II for FSGS, with a clinically relevant bar of roughly a 20% UPCR improvement), AKB-097 (a tissue-targeted anti-C3D complement inhibitor set for an open-label basket trial in IgA nephropathy, lupus nephritis and C3 glomerulopathy), and AKB-9090 (an internally discovered HIF-PHI for cardiac surgery-associated acute kidney injury, now in Phase I). This is meaningful breadth for a sub-$300M market cap, and it is being funded by the Vafseo launch plus a conservative view of Auryxia, which is now facing a second generic entrant on top of the authorized generic. The financials tell the transition story: research & development expense rose to $15M in Q1, up 52% year-over-year, even as net loss deepened to $9.1M from a $6.1M profit a year earlier. Erik Ostrowski notes “...cash resources and cash from operations will be sufficient to fund our current operating plan for at least 2 years” — Erik Ostrowski, Chief Financial Officer · 2026-05-07, with effective net cash near $112M. R&D now consumes roughly a quarter of revenue — an intentional reinvestment of launch cash into second-generation assets.

Launch momentum vs. a tape in drawdown

The oddity is the tape. Akebia shares fell roughly 35% over the 90 trading days into late August and are down ~42% from an April peak, with the full-history return still near -97%. The report itself was objectively positive — revenue growth, patient inflection, adherence repair, pipeline catalysts — yet the equity has kept bleeding. The market appears to be pricing the structural cliff that arrives when the TDAPA add-on payment window closes and Vafseo enters the dialysis bundle in 2027, which would compress net revenue per patient even as utilization grows. The bet embedded in the stock is whether the clinical evidence (the JASN-published Win statistics analysis, the coming VOCAL and VOICE readouts) and DaVita adoption can offset the reimbursement step-down. That is the crux: a company that has finally fixed its operational engine at the exact moment the economics of its largest asset are about to be rebased. Total revenue of $54M is still down 7% year-over-year — Auryxia's decline and inventory noise continue to weigh on the top line — so the Vafseo ramp is not yet large enough to carry the whole P&L. The next 12 months are genuinely binary. If VOCAL (Q4 2026) and VOICE (early 2027) confirm the Win statistics signal and DaVita moves to observed dosing, Akebia has a real path to standard of care in a $1B market. If adherence regresses or the bundle rebasing bites harder than expected, the launch's newfound momentum will have arrived too late. For a $270M company, this is as close to a decisive year as it gets.